AU2013235439B2 - Compositions and methods for regulating hair growth - Google Patents

Compositions and methods for regulating hair growth Download PDF

Info

Publication number
AU2013235439B2
AU2013235439B2 AU2013235439A AU2013235439A AU2013235439B2 AU 2013235439 B2 AU2013235439 B2 AU 2013235439B2 AU 2013235439 A AU2013235439 A AU 2013235439A AU 2013235439 A AU2013235439 A AU 2013235439A AU 2013235439 B2 AU2013235439 B2 AU 2013235439B2
Authority
AU
Australia
Prior art keywords
antagonist
subject
hair
activity
hair growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013235439A
Other languages
English (en)
Other versions
AU2013235439A1 (en
Inventor
George Cotsarelis
Garret FITZGERALD
Luis Garza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2013235439A1 publication Critical patent/AU2013235439A1/en
Application granted granted Critical
Publication of AU2013235439B2 publication Critical patent/AU2013235439B2/en
Priority to AU2018201331A priority Critical patent/AU2018201331A1/en
Priority to AU2019204620A priority patent/AU2019204620A1/en
Priority to AU2021203172A priority patent/AU2021203172A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013235439A 2012-03-21 2013-03-15 Compositions and methods for regulating hair growth Active AU2013235439B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2018201331A AU2018201331A1 (en) 2012-03-21 2018-02-23 Compositions and methods for regulating hair growth
AU2019204620A AU2019204620A1 (en) 2012-03-21 2019-06-28 Compositions and methods for regulating hair growth
AU2021203172A AU2021203172A1 (en) 2012-03-21 2021-05-18 Compositions and methods for regulating hair growth

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613829P 2012-03-21 2012-03-21
US61/613,829 2012-03-21
PCT/US2013/031825 WO2013142295A1 (en) 2012-03-21 2013-03-15 Compositions and methods for regulating hair growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018201331A Division AU2018201331A1 (en) 2012-03-21 2018-02-23 Compositions and methods for regulating hair growth

Publications (2)

Publication Number Publication Date
AU2013235439A1 AU2013235439A1 (en) 2014-10-30
AU2013235439B2 true AU2013235439B2 (en) 2017-11-23

Family

ID=49223241

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013235439A Active AU2013235439B2 (en) 2012-03-21 2013-03-15 Compositions and methods for regulating hair growth
AU2018201331A Abandoned AU2018201331A1 (en) 2012-03-21 2018-02-23 Compositions and methods for regulating hair growth
AU2019204620A Abandoned AU2019204620A1 (en) 2012-03-21 2019-06-28 Compositions and methods for regulating hair growth
AU2021203172A Abandoned AU2021203172A1 (en) 2012-03-21 2021-05-18 Compositions and methods for regulating hair growth

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2018201331A Abandoned AU2018201331A1 (en) 2012-03-21 2018-02-23 Compositions and methods for regulating hair growth
AU2019204620A Abandoned AU2019204620A1 (en) 2012-03-21 2019-06-28 Compositions and methods for regulating hair growth
AU2021203172A Abandoned AU2021203172A1 (en) 2012-03-21 2021-05-18 Compositions and methods for regulating hair growth

Country Status (10)

Country Link
EP (1) EP2827952B1 (enExample)
JP (2) JP6193968B2 (enExample)
KR (1) KR102205774B1 (enExample)
CN (2) CN108938441A (enExample)
AU (4) AU2013235439B2 (enExample)
CA (1) CA2867901A1 (enExample)
EA (1) EA033143B1 (enExample)
ES (1) ES2895660T3 (enExample)
IL (1) IL234740A0 (enExample)
WO (1) WO2013142295A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
EP3178465A1 (en) 2010-12-06 2017-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
US11696883B2 (en) 2014-05-23 2023-07-11 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
WO2015176161A1 (en) * 2014-05-23 2015-11-26 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
CA2983942A1 (en) * 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
PL3347009T3 (pl) 2015-07-08 2022-02-07 Triple Hair Inc. Kompozycja zawierająca resweratrol i melatoninę ograniczająca wypadanie włosów i/lub zwiększająca odrastanie włosów
US12201625B2 (en) * 2015-07-30 2025-01-21 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2
CN106214592B (zh) * 2016-09-09 2019-03-15 美萃国际贸易（上海）有限公司 毛囊营养液组合物及其制备方法
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
GB202005548D0 (en) * 2020-04-16 2020-06-03 Hairclone Ltd Method of determining the androgen-sensitivity of a hair follicle
CN119841890A (zh) * 2025-03-21 2025-04-18 杭州佰倍优生物科技有限公司 一种促进毛囊重建的血蛋白肽及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019171A1 (en) * 2003-08-18 2005-03-03 Astrazeneca Ab Substituted indole derivatives for pharmaceutical composition for treating respiratory diseases
US20050112075A1 (en) * 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
WO2007149312A2 (en) * 2006-06-16 2007-12-27 The Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
WO2008012511A1 (en) * 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity
WO2012078649A1 (en) * 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003097042A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Pgd2 receptor antagonist
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EA011385B1 (ru) 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2004035543A1 (en) 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
EP1435356A1 (en) 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
EP1882937B1 (en) * 2005-05-17 2012-02-22 Taiho Pharmaceutical Co., Ltd. Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease
CN102802621A (zh) * 2009-06-17 2012-11-28 阿德兰斯研究学院有限公司 用于增强真皮细胞的毛原性能力的方法和组合物
KR20120046762A (ko) * 2009-07-31 2012-05-10 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 피부 제형
PH12012501349A1 (en) * 2010-01-06 2013-01-14 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
EP2538963B8 (en) * 2010-02-24 2017-08-02 Advangen International Pty Ltd Method of treatment or prevention of hair loss or for the enhancement of hair growth
US20100172865A1 (en) * 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019171A1 (en) * 2003-08-18 2005-03-03 Astrazeneca Ab Substituted indole derivatives for pharmaceutical composition for treating respiratory diseases
US20050112075A1 (en) * 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
WO2007149312A2 (en) * 2006-06-16 2007-12-27 The Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
US20110021599A1 (en) * 2006-06-16 2011-01-27 George Cotsarelis Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
WO2008012511A1 (en) * 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity
WO2012078649A1 (en) * 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Garza, LA et al (2009) Evidence that Prostaglandin D2 contributes to development of Androgenetic Alopecia. Journal of Investigative Dermatology 129: S98 (Abstract 584) *
Garza, LA et al (2010) The role of Prostaglandin D2 and its receptor DP-2 in promotion of Androgenetic Alopecia. Journal of Investigative Dermatology 130: S103 (Abstract 615) *

Also Published As

Publication number Publication date
JP6193968B2 (ja) 2017-09-06
AU2019204620A1 (en) 2019-07-18
JP2015512393A (ja) 2015-04-27
ES2895660T3 (es) 2022-02-22
CN104602763B (zh) 2018-08-21
KR20140146133A (ko) 2014-12-24
CN104602763A (zh) 2015-05-06
EA033143B1 (ru) 2019-09-30
KR102205774B1 (ko) 2021-01-20
EP2827952A1 (en) 2015-01-28
AU2021203172A1 (en) 2021-06-10
CA2867901A1 (en) 2013-09-26
AU2018201331A1 (en) 2018-03-15
AU2013235439A1 (en) 2014-10-30
CN108938441A (zh) 2018-12-07
EP2827952A4 (en) 2016-03-30
WO2013142295A1 (en) 2013-09-26
EP2827952B1 (en) 2021-07-07
JP2017197585A (ja) 2017-11-02
IL234740A0 (en) 2014-11-30
EA201491737A1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
AU2013235439B2 (en) Compositions and methods for regulating hair growth
Kobayashi et al. A role of melatonin in neuroectodermal‐mesodermal interactions: the hair follicle synthesizes melatonin and expresses functional melatonin receptors
AU2017267278B2 (en) Compounds for promoting hair growth and/or inhibiting or delaying hair loss in humans, and compositions for such uses
KR102746106B1 (ko) 트리파타이트(tripartite) 안드로겐 수용체 제거제, 그 방법 및 용도
EP3585381B1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
US20150072963A1 (en) Compositions and methods for regulating hair growth
WO2018039612A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
JPH10508828A (ja) 毛髪成長の制御
EP1317915A1 (en) Hair nourishments and method of screening the same
WO2021147740A1 (zh) Mapk/erk通路抑制剂在拮抗皮肤老化与辐射性皮肤早衰中的应用
JP4268329B2 (ja) 養毛料、毛髪退行期移行抑制剤等の予防あるいは治療用組成物
US20250170150A1 (en) Olfactory receptor 2a4/7 agonist for promoting hair growth and improving aesthetic aspect
Xiao et al. Preliminary study on platelet-rich plasma enhancing autophagy level and promoting hair growth in androgenetic alopecia model mice
CN104717964A (zh) 用于预防和/或治疗毛发失调的伊罗替罗及其组合物
KR20140131193A (ko) 태반성장인자를 표적으로 하는 모발 성장 조절 방법 및 조성물
JP2012502918A (ja) 脱毛を治療する、又は、脱毛の発症を遅らせるための組成物
Blume-Peytavi et al. P-01: A pilot study-24 weeks topical treatment by latanoprost 0.1% increases hair growth in androgenetic alopecia
HK40015839A (en) Compositions and methods for promoting hair growth with mpc1 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)